Skip to main
PAVM
PAVM logo

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. is highlighted for its promising upside potential in valuation, which effectively balances the inherent risks associated with its operations and the opportunities that lie ahead. The company's diversified product pipeline, which includes innovations like EsoGuard, esocheck, and the Veris Cancer Care Platform, indicates strong growth prospects, particularly in the upcoming years of 2025 and 2026. Furthermore, PAVmed's current valuation is considered attractive, supporting a positive sentiment about its trajectory as the company advances its early-stage products toward more significant commercial success.

Bears say

PAVmed Inc reported a pro forma net loss of $0.8 million, translating to an earnings per share (EPS) of $(0.05), which is significantly better than the prior estimates that projected a loss ranging between $(0.13) and $(0.25). This financial performance is overshadowed by a decline in the usage of its flagship EsoGuard test, with processed tests dropping to 2,756 in Q2 from 3,034 in Q1 and an overall downward trend from previous quarters. Additionally, the company faces substantial risks, including liquidity challenges, regulatory hurdles, market competition, and shifts in healthcare priorities, all of which cast a shadow over its ability to sustain growth and profitability.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.